The metabolic epicenter of supratentorial gliomas: A 1h-mrsi study

Canadian Journal of Neurological Sciences

Volumn 36, Issue 6, 2009, Pages 696-706

  Sankar, Tejas ^a   Kuznetsov, Yevgeniy E ^b   Ryan, Robert W ^a   Caramanos, Zografos ^b   Antel, Samson B ^b   Arnold, Douglas L ^b   Preul, Mark C ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; CANCER SURVIVAL; DIAGNOSTIC IMAGING; GLIOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT PLANNING; TUMOR DIAGNOSIS; TUMOR LOCALIZATION;

EID: 70350343422     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100008301     Document Type: Article

References (61)

1. Apuzzo MLJ. Commentary: epidemiology and data analysis. In: Apuzzo MLJ, editor. Malignant cerebral glioma. Park Ridge, Ill: American Association of Neurological Surgeons; 1990. p. 111.
2. Ahlbom A, Rodvall Y. Brain tumour trends. Lancet. 1989;334: 1272-1273
3. Salcman M. Epidemiology and factors affecting survival. In: Apuzzo MLJ, editor. Malignant cerebral glioma. Park Ridge, Ill: American Association of Neurological Surgeons; 1990. p. 95-109.
4. Cohadon F, Aouad N, Rougier A, Vital C, Rivel J, Dartigues JF. Histologic and non-histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neurooncol. 1985;3: 105-111
5. Curran WJ, Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710
6. Miller PJ, Hassanein RS, Giri PG, Kimler BF, O'Boynick P, Evans RG. Univariate and multivariate statistical analysis of high-grade gliomas: The relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys. 1990;19:275-280
7. Kim TS, Halliday AL, Hedley-Whyte ET, Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg. 1991;74:27-37.
8. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983;52:997-1007.
9. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983;67:121-132
10. Kinsella TJ, Collins J, Rowland J, Klecker Jr R, Wright D, Katz D, et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol. 1988;6:871-879
11. Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery. 1988;22:465-473
12. Nelson DF, Nelson JS, Davis DR, Chang CH, Griffin TW, Pajak TF. Survival and prognosis of patients with astrocytoma with atypical or anaplastic features. J Neurooncol. 1985;3:99-103.
13. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J, Nikolic N. Clinical prognostic factors in patients with malignant glioma treated with combined modality approach. Am J Clin Oncol. 2004;27:195-204.
14. Mikkelsen T, Enam SA, Rosenblum ML. Invasion in malignant glioma. In: Winn HR, Youmans JR, editors. Youmans Neurological Surgery. Philadelphia: Saunders; 2004. p. 757-770
15. Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med. 1996;2:323-325
16. Preul MC, Caramanos Z, Leblanc R, Villemure JG, Arnold DL. Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors. NMR Biomed. 1998;11:192-200.
17. McBride DQ, Miller BL, Nikas DL, Buchthal S, Chang L, Chiang F, et al. Analysis of brain tumors using 1H magnetic resonance spectroscopy. Surg Neurol. 1995;44:137-144
18. Meyerand ME, Pipas JM, Mamourian A, Tosteson TD, Dunn JF. Classification of biopsy-confirmed brain tumors using singlevoxel MR spectroscopy. AJNR Am J Neuroradiol. 1999;20: 117-123
19. Castillo M, Kwock L, Scatliff J, Mukherji SK. Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. Magn Reson Imaging Clin N Am. 1998;6:1-20.
20. Alger JR, Frank JA, Bizzi A, Fulham MJ, DeSouza BX, Duhaney MO, et al. Metabolism of human gliomas: Assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology. 1990;177:633-641
21. Fulham MJ, Bizzi A, Dietz MJ, Shih HH, Raman R, Sobering GS, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology. 1992;185: 675-686
22. Fountas KN, Kapsalaki EZ, Gotsis SD, Kapsalakis JZ, Smisson III HF, Johnston KW, et al. In vivo proton magnetic resonance spectroscopy of brain tumors. Stereotact Funct Neurosurg. 2000; 74:83-94.
23. Tamiya T, Kinoshita K, Ono Y, Matsumoto K, Furuta T, Ohmoto T. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiol. 2000;42: 333-338
24. Wilken B, Dechent P, Herms J, Maxton C, Markakis E, Hanefeld F, et al. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Pediatr Neurol. 2000;23:22-31.
25. Shimizu H, Kumabe T, Tominaga T, Kayama T, Hara K, Ono Y, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. AJNR Am J Neuroradiol. 1996;17: 737-747
26. Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day MR, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR. 2001;22:604-612
27. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: A serial proton magnetic resonance spectroscopy imaging study. J Neurosurg. 1997;87: 516-524 (Pubitemid 27430397)
28. McKnight TR, Lamborn KR, Love TD, Berger MS, Chang S, Dillon WP, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg. 2007;106:660-666
29. Matsumura A, Isobe T, Anno I, Takano S, Kawamura H. Correlation between choline and MIB-1 index in human gliomas. A quantitative proton MR spectroscopy study. J Clin Neurosci. 2005;12:416-420
30. Kwan RK, Evans AC, Pike GB. MRI simulation-based evaluation of image-processing and classification methods. IEEE Trans Med Imaging. 1999;18:1085-1097
31. Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: A phase II study. Int J Radiat Oncol Biol Phys. 1994;30:1179-1185
32. Jeremic B, Grujicic D, Antunovic V, Djuric L, Shibamoto Y. Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study. Am J Clin Oncol. 1995;18:449-453
33. Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, et al. Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: A phase II study. Radiother Oncol. 1999;51:27-33.
34. Jeremic B, Shibamoto Y, Grujicic D, Stojanovic M, Milicic B, Nikolic N, et al. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study. J Neurooncol. 2001;51:133-141
35. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239-244
36. Curran WJ, Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Nelson DF. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol. 1992;12:219-227
37. Gehan EA, Walker MD. Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr. 1977;46:189-195
38. Phuphanich S, Ferrall S, Greenberg H. Long-term survival in malignant glioma. Prognostic factors. J Fla Med Assoc. 1993;80:181-184
39. Kowalczuk A, Macdonald RL, Amidei C, Dohrmann III G, Erickson RK, Hekmatpanah J, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery. 1997;41:1028-1036
40. Jelsma R, Bucy PC. Glioblastoma multiforme: its treatment and some factors affecting survival. Arch Neurol. 1969;20:161-171
41. Jelsma R, Bucy PC. The treatment of glioblastoma multiforme of the brain. J Neurosurg. 1967;27:388-400.
42. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg. 1989;71:487-493
43. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg. 1993;78: 767-775
44. Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol. 2001;52: 161-171
45. Larjavaara S, Mantyla R, Salminen T, Haapasalo H, Raitanen J, Jaaskelainen J, et al. Incidence of gliomas by anatomic location. Neuro Oncol. 2007;9:319-325
46. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas: comparison with glioblastomas and review of hypothesis. Cancer. 2004;100:2622-2626
47. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323-1329
48. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753-766
49. Scherer HJ. Structural development in gliomas.Am J Cancer. 1938; 34:333-351
50. Matsukado Y, MacCarty CS, Kernohan JW. The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg. 1961;18:636-644
51. Rosenblum ML, Eisenberg AD, Norman D. Brain tumor invasion: clinical patterns of malignant astrocytoma spread [abstract]. J Neurosurg. 1992;76:383A.
52. Enam SA, Eisenberg AD, Norman D, Rosenblum ML. Patterns of spread and recurrence of glioma: studies by neuroimaging. In: Mikkelsen T, Bjerkvig R, Laerum OD, Rosenblum ML, editors. Brain tumor invasion: biological, clinical, and therapeutic considerations. New York: Wiley-Liss; 1998. p. 133-159
53. Salazar OM, Rubin P. The spread of glioblastoma multiforme as a determining factor in the radiation treated volume. Int J Radiat Oncol Biol Phys. 1976;1:627-637
54. Piepmeier JM. Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. J Neurosurg. 1987;67:177-181
55. McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J. Treatment and survival of low-grade astrocytoma in adults-1977-1988. Neurosurgery. 1992;31:636-642
56. Laws ER, Jr., Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. 1984;61:665-673
57. Muller W, Afra D, Schroder R. Supratentorial recurrences of gliomas. Morphological studies in relation to time intervals with astrocytomas. Acta Neurochir (Wien). 1977;37:75-91. (Pubitemid 8083330)
58. North CA, North RB, Epstein JA, Piantadosi S, Wharam MD. Lowgrade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer. 1990;66:6-14.
59. Soffietti R, Chio A, Giordana MT, Vasario E, Schiffer D. Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery. 1989;24:686-692
60. Vertosick FT Jr, Selker RG, Arena VC. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery. 1991;28:496-501.
61. Lim DA, Cha S, Mayo MC, Chen M-H, Keles E, VandenBerg S, et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neurooncol. 2007;9:424-429